STAT6 – Talk Bio

Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

5 days ago talkbio0Tagged Asthma, biotech collaboration, DEL-AI, Dermatitis, Atopic, Drug Discovery, Licensing Deal, Nurix, NX-3911, protein degrader, sanofi, STAT6

Sanofi; Nurix Therapeutics; STAT6; NX-3911; protein degrader; atopic dermatitis; asthma; drug discovery; licensing deal; DEL-AI platform; biotech collaboration

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

5 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

5 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

7 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2